Despite changes to regulations, Hong Kong IPOs are still set to remain robust this year with six firms already listing this week, according to Frank Bi, Asia head of corporate transactions at law firm Ashurst.
If approved, the fund will become the first private credit infrastructure fund to be listed on HKEX. The fund invests in assets across renewables, power, utilities, data centres, telecommunications, transport, healthcare and accommodation.
The HK$155 a share offer is a 33% premium over Hang Seng's 30-day average closing price; HSBC already owns 63% of the HKEX-listed bank. Hang Seng's after tax profits declined 30% in H1 2025. HSBC has paused buybacks.
Hong Kong-listed biotech firms are outperforming as Trump’s policies cause firms to change course from their traditional US destination, with more HKEX listings expected in the second half of 2025; experts shared their views at BIOHK.